Recently, the Trelagliptin Succinate NDA has captured pharmaceutical headlines as it was accepted by the Japanese Ministry of Health, Labour and Welfare. As a unique once weekly treatment for type 2 diabetes, Trelagliptin Succinate is an effectual dipeptidyl peptidase-IV inhibitor. As one of the few providers in the world of Trelagliptin Succinate, LGM Pharma offers[…]
Trelagliptin Succinate NDA in Japan Captures Global Attention of Pharmaceutical World
Anti-Diabetic, Drug Research & Development API, Gliptin, NDA Tags: Sitagliptin Phosphate Apr 09, 2014
Gliptins Give Researchers a Pleasant Cardiovascular Surprise
Anti-Diabetic, Drug Research & Development API, Gliptin Tags: LinagliptinSaxagliptinSitagliptin Phosphate Oct 12, 2011
DDP-4 inhibitors, commonly known as Gliptins, are a relatively new group of drugs. They are drugs normally used for diabetes control, however, this year it was discovered that they may play a greater heart-protective role in patients with existing cardiovascular comorbidities. According to the report published last month in Medpage Today, researchers found that patients[…]
